Literature DB >> 8821747

HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures.

B A Bennett1, D E Rusyniak, C K Hollingsworth.   

Abstract

HIV-1-associated cognitive/motor dysfunction is a frequent neurological complication of acquired immunodeficiency syndrome (AIDS) and has been termed AIDS dementia complex (ADC). The HIV-1 envelope glycoprotein gp120 has been implicated in producing brain injury associated with ADC. The purpose of the present study was to determine if gp120-induced neurotoxicity is associated with damage to dopaminergic systems. Exposure of rat midbrain dopamine cultures to gp120 for 3 days reduced the ability of dopaminergic cells to transport this amine and also resulted in a reduction in dopamine neuron process length while it did not alter either dopamine cell number or the total number of neuronal cells. These detrimental effects of gp120 were prevented by an NMDA receptor antagonist (MK-801) or by preincubation with anti-gp120 antibody. These results suggest that dopaminergic neuronal damage may contribute to the manifestations of AIDS dementia complex.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8821747     DOI: 10.1016/0006-8993(95)01166-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  31 in total

1.  Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage.

Authors:  Shuxian Hu; Wen S Sheng; James R Lokensgard; Phillip K Peterson; R Bryan Rock
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

2.  Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.

Authors:  Italo Mocchetti; Alessia Bachis; Rachel L Nosheny; Gianluigi Tanda
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

3.  Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.

Authors:  Irene Guendel; Sergey Iordanskiy; Rachel Van Duyne; Kylene Kehn-Hall; Mohammed Saifuddin; Ravi Das; Elizabeth Jaworski; Gavin C Sampey; Svetlana Senina; Leonard Shultz; Aarthi Narayanan; Hao Chen; Benjamin Lepene; Chen Zeng; Fatah Kashanchi
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

4.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

Review 5.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

6.  Increased Sensitivity to Cocaine Self-Administration in HIV-1 Transgenic Rats is Associated with Changes in Striatal Dopamine Transporter Binding.

Authors:  Scot McIntosh; Tammy Sexton; Lindsey P Pattison; Steven R Childers; Scott E Hemby
Journal:  J Neuroimmune Pharmacol       Date:  2015-03-10       Impact factor: 4.147

7.  Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization.

Authors:  Alessia Bachis; Eugene O Major; Italo Mocchetti
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

8.  Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy.

Authors:  Victoria C J Wallace; Julie Blackbeard; Timothy Pheby; Andrew R Segerdahl; Meirion Davies; Fauzia Hasnie; Susan Hall; Stephen B McMahon; Andrew S C Rice
Journal:  Pain       Date:  2007-04-12       Impact factor: 6.961

9.  Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains.

Authors:  Adarsh M Kumar; J B Fernandez; Elyse J Singer; Deborah Commins; Drenna Waldrop-Valverde; Raymond L Ownby; Mahendra Kumar
Journal:  J Neurovirol       Date:  2009-05       Impact factor: 2.643

10.  Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice.

Authors:  Brook L Henry; Mark A Geyer; Mahalah Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Brain Res       Date:  2012-08-31       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.